Lipan

Quick links to important sections

Lipan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipan

Property Description
Active Ingredient Meclozine (Meclizine hydrochloride)
Form Oral tablet, Chewable tablet
Pharmacological Class First-generation antihistamine, Anticholinergic antiemetic
Common Use Relief of dizziness, vertigo, and motion-related nausea
Origin Synthetic piperazine derivative

What Type of Medicine is Lipan?

The medicine known commercially as Lipan contains meclozine, also formally known as meclizine hydrochloride, as its single active component. Meclozine is classified pharmacologically as a first-generation antihistamine that operates as a nonselective H1 receptor antagonist. Structurally, this agent is a synthetic piperazine derivative. This specific classification is clinically recognized for its ability to affect the central nervous system, establishing its use as a vestibular suppressant. This supports the medicine's role in calming the signals responsible for inner ear disturbances and sensory confusion.

Composition, Form, and General Purpose

Lipan is formulated as a single-active ingredient product delivered for the oral route, commonly available in solid dosage forms such as a tablet or a chewable tablet. Its primary therapeutic function stems from its dual action on the central nervous system, reducing the excitability of the labyrinth (the inner ear's balance structure) and suppressing the central reflexes that trigger sickness. Through this mechanism, meclozine serves to stabilize a patient's equilibrium. The drug is used as an antiemetic (anti-nausea) and antivertigo agent to alleviate the uncomfortable sensations of dizziness, vertigo, nausea, and vomiting associated with motion and balance issues.

Regulatory References

  1. First-generation H1-antihistamines
  2. Meclizine hydrochloride tablet
  3. DailyMed, NIH

What side effects are possible with Lipan?

Possible side effects and safety information

The safety profile of Lipan, which contains the active ingredient meclizine, is formally defined by effects related to its action on the central nervous and anticholinergic systems, as classified in official regulatory documents.

Common Adverse Reactions and System-Organ Classes

Adverse reactions that are frequently observed and officially listed include drowsiness, dry mouth, fatigue, and headache. These effects are categorized primarily under Nervous System Disorders and Gastrointestinal Disorders. Less common effects that have been documented include blurred vision, categorized under Eye Disorders, and urinary retention, under Renal and Urinary Disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling documents address the potential for rare but clinically significant adverse reactions, including anaphylactic reaction and severe hypersensitivity reactions. Meclizine is contraindicated in individuals with known hypersensitivity to the medication. Furthermore, caution is advised for patients with certain pre-existing conditions that may be exacerbated by its anticholinergic properties, such as glaucoma or prostatic hypertrophy.

Population-Specific Safety Considerations

The prescribing information includes specific cautions for the older adult (geriatric) population, reflecting their increased susceptibility to central nervous system effects, such as heightened sedation and confusion. An increased risk of CNS depression is also noted when Meclizine is administered concurrently with alcohol or other sedating agents. Safety and effectiveness have not been established for use in children under 12 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information summarizes the officially documented manifestations and required emergency actions for Lipan (Meclizine hydrochloride) overdose, as detailed in governmental regulatory information.

Documented Overdose Manifestations

Population Primary Documented Manifestations
Adults CNS depression (drowsiness, progressing to coma), convulsions, and hypotension.
Children CNS stimulation (seizures, hallucinations, trouble sleeping) and anticholinergic effects.

Immediate Emergency Actions

In all cases of suspected overdose, seek immediate medical attention or contact a Poison Control Center right away. Immediate medical help is mandatory if the person exhibits severe or life-threatening signs. Regulatory guidance instructs calling emergency services immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Supportive Care and Antidote Status

Management is primarily symptomatic and supportive treatment to maintain vital functions, as regulatory documentation states that no specific antidote is known. Procedures to reduce drug absorption, such as gastric emptying or administration of activated charcoal, may be required. Population-specific warnings note that hypotension is a particular risk in the elderly, while CNS stimulation is more likely in children.

Therapeutic Uses of Lipan

What Lipan Treats: Main Uses and Benefits

The medication, which contains the active ingredient fenofibrate (a type of fibrate), is used for managing lipid imbalances. Its main function is applied in addressing conditions presenting with systemic or localized discomfort related to high levels of fats (lipids) in the bloodstream. It is considered relevant as an adjunct to diet and lifestyle changes.

The primary therapeutic domain involves conditions characterized by periods of heightened symptoms related to mixed dyslipidemia and severe hypertriglyceridemia in adults. Fenofibrate may assist with addressing symptom clusters that may become intense or disruptive by supporting the reduction of elevated levels of Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Triglycerides (TG), and contributes to increased levels of High-Density Lipoprotein Cholesterol (HDL-C). This supportive approach is utilized across conditions presenting with acute episodes of very high triglycerides. The primary therapeutic areas generally involve patients with primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.

The medication provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

“This approach plays a role in managing symptoms linked to organ-specific functional stress that may be associated with lipid imbalances.”

Quick Fact: Relief for Elevated Lipids

Eligibility and Restrictions for Use

Who Can and Cannot Use Lipan?

The determination of who is eligible to use Lipan (meclizine) is strictly defined by regulatory documents, which establish specific population rules and contraindications.

Absolute Contraindications: You must not use this medication if you have a documented history of hypersensitivity or allergy to the active ingredient, meclizine, or to any of the other components in the product formulation.

Age and Use Restrictions: The medicine is not recommended for children under 12 years of age. Regulatory agencies state that the safety and effectiveness have not been established for use in this pediatric population. For elderly patients, official labeling advises that caution be exercised, often recommending careful dose selection due to the increased frequency of reduced kidney or liver function in older adults.

Medical Conditions Requiring Caution: Use requires special caution in patients with specific pre-existing conditions. These include glaucoma, asthma, and enlargement of the prostate gland, primarily due to the drug's known anticholinergic effects. Additionally, caution is mandatory for individuals with impaired hepatic (liver) or renal (kidney) function, as these issues may affect the body’s ability to clear the medicine.

Pregnancy and Breastfeeding: If you are pregnant, the medicine should be used only if clearly necessary. Caution is also officially advised for nursing mothers as regulatory data states it is currently unknown whether the medication is transferred into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lipan, which contains meclizine, has an official interaction profile based on two primary categories of additive effects documented in regulatory labeling.

Interaction Scope

Category Documented Interacting Substances / Conditions
Pharmacodynamic Central Nervous System (CNS) Depressants, Anticholinergic Agents, Alcohol, Sedative Herbal Products
Pharmacokinetic CYP2D6 Inhibitors

Interacting Product Categories: Co-administration with Central Nervous System (CNS) Depressants, including alcohol, tranquilizers, and sedatives, may result in increased CNS depression. This effect is formally cited in prescribing information as a restriction due to the potential for intensified effects on mental alertness.

Co-administration with Anticholinergic Agents may lead to cumulative anticholinergic effects, which is an officially documented pharmacodynamic outcome.

Metabolic Interaction Notes: Based on in vitro studies, meclizine is metabolized by the enzyme CYP2D6. Therefore, regulatory documents state there is a possibility for a drug interaction when Lipan is administered concurrently with CYP2D6 inhibitors. This requires monitoring for potential increases in meclizine exposure.

Population-Specific Notes: Regulatory cautions note that the potential for increased sedation and anticholinergic effects is a specific consideration in the elderly population when co-administered with other interacting agents, due to generally reduced renal function.

Mechanism of Action

How Lipan Works

Lipan is a selective inhibitor of farnesyl pyrophosphate synthase (FPPS), an essential enzyme within the mevalonate pathway of the osteoclast. By binding to the active site of FPPS, Lipan prevents the conversion of geranyl diphosphate to farnesyl diphosphate.

This blockade disrupts the subsequent synthesis of necessary isoprenoids, including geranylgeranyl diphosphate, required for the prenylation of small GTPases such as Rho and Rac. The non-prenylated GTPases cannot localize to the ruffled border membrane of the osteoclast, leading to a loss of the functional cytoskeleton.

This incapacitation of the osteoclast reduces its resorptive activity, thereby reducing the rate of bone mineral dissolution. By disrupting this cascade, Lipan modulates the ratio of bone resorption to bone formation. This action results in a net decrease in the release of calcium and phosphate from bone matrix. The inhibition profile of Lipan demonstrates a high affinity for the target enzyme.

Dosage and Administration Information

How Lipan is Used

Lipan (meclizine hydrochloride) is administered exclusively via the oral route, with specific procedural requirements depending on the form received. The medicine is available as non-chewable tablets in strengths of 12.5 mg, 25 mg, and 50 mg, and as a 25 mg chewable tablet.

Administration instructions define how the drug must be physically ingested: non-chewable tablets must be swallowed whole and should not be crushed or broken. In contrast, chewable tablets must be fully chewed or crushed before being swallowed and should not be taken whole. The medication can be taken with or without food.


Official Dosing and Scheduling

The dosage and frequency are determined by the condition being managed. All dosing is based on established guidelines for individuals 12 years of age and older.

Condition Standard Adult Dosing Range Frequency Pattern
Vertigo 25 mg to 100 mg daily Administered in divided doses daily
Motion Sickness (Prevention) Initial dose of 25 mg to 50 mg Initial dose 1 hour prior to travel; repeated every 24 hours as needed

For motion sickness, the time-contingent nature of the dosing requires the first dose to be taken one hour before anticipated motion exposure. For vertigo, the duration of use is determined by the required period of symptomatic management, while motion sickness dosing continues every 24 hours for the duration of the journey. In older adults, a lower starting dose at the end of the established range is generally utilized.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lipan (Meclizine)

The research available for Lipan, which contains the active ingredient meclizine, examines its use in the context of conditions related to motion and inner-ear function. The evidence landscape primarily consists of controlled studies and clinical experience over several decades, which has been evaluated by health authorities.


Evidence for Use in Motion Sickness Prevention

Studies examined meclizine for motion sickness primarily involves Randomized Controlled Trials (RCTs) and field trials. These studies was evaluated in healthy adult volunteers, typically measuring outcomes related to physical discomfort during a single episode of motion. Studies monitored patient-reported outcomes describing perceived discomfort, specifically the frequency and intensity of nausea, vomiting, and dizziness. Research exploring short-term symptom changes contributing to the evidence base for prevention.

However, the results apply only to the populations studied, which are mainly young, healthy adults. Research exploring short-term changes provides context but not individual predictions for all users. Furthermore, the observed patterns in studies of common motion may not translate consistently to extreme conditions.


Evidence for Use in Vertigo Management

Meclizine was evaluated in settings involving the symptomatic management of vertigo, which is a condition characterized by fluctuating or episodic manifestations, often linked to vestibular diseases of the inner ear. The research base includes double-blind studies primarily focusing on patients with vestibular origin vertigo.

These studies monitored outcomes describing episodic or acute changes, such as the severity and frequency of vertigo attacks and associated symptoms like nausea. Findings describe patterns observed in the studies that were reported contributing to the available evidence landscape as a vestibular suppressant during periods of increased symptom activity.


What Remains Uncertain in the Evidence Base

The evidence landscape highlights what is known—and what is still uncertain—about meclizine's use. Research examined the effects of meclizine, with most studies focused on short-term observation of acute symptoms rather than prolonged maintenance. Long-term effects are not fully established beyond the acute treatment window, particularly concerning its use for chronic dizziness or balance issues.

Data for certain groups remain insufficient, especially for children under the age of 12. Scientific literature notes that continuous or prolonged use of vestibular suppressants was associated with potential for interference with vestibular compensation, which is the brain's natural ability to recover.

Key Studies & References Meclizine Hydrochloride Tablets Prescribing Information and Monograph

Frequently Asked Questions (FAQ)

Common questions about Lipan (FAQ)


Q: Is Lipan available over the counter in any country?

The active ingredient in Lipan, meclizine, is available as both a prescription and an over-the-counter medicine for specific indications, such as motion sickness. This availability depends on the regulations of the local health authority.


Q: What is the difference between Lipan and its generic version?

According to general regulatory standards, the generic version contains the exact same active ingredient (meclizine) at the same strength. It must also meet the same official standards for use, safety, and effectiveness as the brand-name product.


Q: Is Lipan considered a controlled substance?

Regulatory documents from the DEA (Drug Enforcement Administration) confirm that the active ingredient, meclizine, is not classified as a controlled substance under the Controlled Substances Act. This classification is used to regulate drugs with a potential for dependence or misuse.


Q: Does Lipan have a potential for dependence or misuse?

The drug is not classified as a controlled substance by the DEA. This status generally indicates that it does not have a recognized potential for dependence or misuse as defined by federal regulations.


Q: What does 'contraindicated' mean in the context of Lipan's use?

The term 'contraindicated' generally means that a medication must not be used because the potential risk of harm outweighs any potential benefit in that specific patient or condition. In the context of Lipan, it applies to individuals with a known hypersensitivity to the drug.


Q: If I am taking Lipan, can I still drive or operate machinery?

Official labeling advises caution due to the possibility of drowsiness occurring with use. Official labeling advises that individuals should avoid driving a car or operating dangerous machinery until they determine how the medication affects their alertness.


Q: Is Lipan ever used in combination with other [Drug class] medicines?

Regulatory documents describe the potential for interactions when Lipan is administered concurrently with other Central Nervous System (CNS) depressants. Due to the possibility of increased CNS effects, caution is advised with such combinations.


Q: Can Lipan be used during pregnancy or while breastfeeding?

Official documents state that the drug should be used during pregnancy only if clearly needed. Furthermore, because it is not known whether the drug is excreted in human milk, caution is advised if the medication is administered to a nursing woman.


Q: Does Lipan have a 'black box warning' in the US?

Official FDA labeling for this drug does not include a Boxed Warning, which is sometimes referred to informally as a 'black box warning'. This type of warning is reserved for serious risks of a medication.


Q: How quickly should someone expect to feel the effects of Lipan?

For the prevention of motion sickness, the initial dose is officially directed to be taken one hour before anticipated travel. This timing suggests that the onset of action occurs within the period of one hour.


Q: Does taking Lipan require routine blood tests or monitoring?

Official labeling does not mandate routine blood tests for all users. However, caution is noted in the official documentation for patients with certain pre-existing conditions, such as hepatic or renal impairment.


Q: What happens if I miss a scheduled time to use Lipan?

Regulatory patient information describes general approaches for missed doses when the medication is taken on a scheduled basis, which typically involves taking the dose when remembered unless it is close to the next scheduled dose.


Q: What is the longest period of time Lipan is typically used for?

Official labeling for motion sickness specifies that dosing may be repeated every 24 hours for the duration of anticipated travel. For vertigo management, the length of time Lipan is used is determined by the required period of symptomatic management. Research evidence primarily focuses on short-term observation of acute symptoms, and prolonged effects are not the subject of most existing studies.


Q: Is it normal to feel [Symptom like mild nausea] when starting Lipan?

Official regulatory documents cite vomiting as an adverse reaction that has been reported with the use of this medication. Common adverse reactions listed in official documents include drowsiness, dry mouth, and fatigue.


Q: Can Lipan affect my mood or sleep patterns?

Common adverse reactions listed in regulatory documents include drowsiness and fatigue, which are related to sleep. Changes in mood or specific sleep patterns like insomnia are not typically listed as reported adverse effects.


Q: Does Lipan cause issues with dental health?

Official regulatory labeling lists dry mouth as a common adverse reaction associated with the use of the medication. No official source directly lists dental health issues. Dry mouth is a recognized side effect linked to the drug’s anticholinergic properties.


Q: Does the time of day matter when using Lipan?

For motion sickness, the first dose is time-contingent and must be taken one hour before travel. For vertigo, the dosing is administered in divided doses daily. The official label does not specify a required time of day, such as morning or evening, for these divided doses.


Q: Why does the label say Lipan is for 'short-term' use only?

The official dosing schedule for motion sickness specifies use every 24 hours only for the duration of travel, which implies acute use. Furthermore, scientific literature has historically focused on short-term observation of acute symptoms rather than prolonged maintenance use.


Q: Why is Lipan sometimes called a [Class of drug]?

The active ingredient in Lipan, meclizine, is described in official documents as an antihistamine. This categorization is based on its chemical structure and its mechanism of action as evaluated by regulatory bodies.


Q: Is Lipan the same type of medicine as [similar drug name]?

Official documents describe the active ingredient, meclizine, as an antihistamine. However, regulatory labeling does not provide comparisons of Lipan to other specific similar medicines.


Q: Are there any specific vitamins or supplements that interact with Lipan?

Official documents caution against the use of sedative herbal products due to the risk of increased central nervous system (CNS) depression. The labeling does not generally detail interactions with specific non-sedative vitamins or minerals.


Q: Can I take Lipan with over-the-counter pain relievers like ibuprofen?

The official product information focuses warnings on interactions with CNS depressants and anticholinergic agents. Non-sedating over-the-counter pain relievers, such as ibuprofen, are generally not specified in these cautionary statements.


Q: Is Lipan known to interact with other prescription medications like blood thinners?

Official labeling identifies specific interacting drug classes, including CNS Depressants and CYP2D6 Inhibitors. The regulatory documents do not list blood thinners (anticoagulants) as a specific known interaction.


Q: Can people with [Chronic condition like diabetes] generally use Lipan?

Official warnings list specific pre-existing conditions, such as glaucoma or prostatic hypertrophy, where use requires caution due to the drug's anticholinergic properties. General eligibility for other common chronic conditions is not specifically detailed in the official contraindication or caution sections.


Q: Are there specific foods I should avoid while using Lipan?

Official labeling states the medication can be taken with or without food. The only specific caution mentioned in the interaction profile is the consumption of alcohol, due to the risk of increased central nervous system effects.

How should Lipan be stored and disposed of?

Storage and Disposal Information

Lipan (fenofibrate) must be stored under specific conditions to maintain stability and effectiveness. The product should be kept at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F).

It is required to store the tablets in a tight container and protect them from moisture and light.

To ensure safety, the medication must always be stored out of the reach of children.

For disposal, unused or expired Lipan should not be flushed down the toilet. The regulatory preferred method is to utilize a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag or container, and placed in the household trash, following official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipan found in:

A-Z Index: